MDIT (Medite Cancer Diagnostics) Total Long-Term Liabilities : $6.59 Mil (As of Sep. 2018)

View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Medite Cancer Diagnostics's Total Long-Term Liabilities for the quarter that ended in Sep. 2018 was $6.59 Mil.

Medite Cancer Diagnostics Total Long-Term Liabilities Historical Data

The historical data trend for Medite Cancer Diagnostics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics Total Long-Term Liabilities Chart

Medite Cancer Diagnostics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Long-Term Liabilities

Get a 7-Day Free Trial

1.57

3.41

3.05

2.20

6.40

Medite Cancer Diagnostics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Total Long-Term Liabilities	Get a 7-Day Free Trial															6.73	6.40	6.67	6.88	6.59

Medite Cancer Diagnostics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Medite Cancer Diagnostics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medite Cancer Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

10524 Moss Park Road, Suite 204-357, Orlando, FL, USA, 32832

Website

http://www.medite-group.com

Medite Cancer Diagnostics Inc is a US-based company that specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology, and marketing of molecular biomarkers. The company manufactures medical devices and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company operates through a single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

Executives

Lewis William Austin Iv	director, 10 percent owner	201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles	director	2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson	director	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics Headlines

No Headlines